1.45% -0.00135

Dopo l'orario di chiusura: .09 -0.00175 -1.91%

Galera Therapeutics Inc (GRTX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché GRTX Giù? Forum Previsione

Galera Therapeutics Inc Borsa (GRTX) Ultime notizie

Galera Therapeutics Inc (GRTX)

Galera Therapeutics Inc Borsa (GRTX) Ultime notizie

Parvinder Singh Hyare Backs Obsidian Deal at Galera Therapeutics with 6.65% Stake - TradingView

Parvinder Singh Hyare (NASDAQ: GRTX) discloses 6.6% Galera stake after preferred conversion - Stock Titan

Galera Therapeutics (GRTX) merger with Obsidian; OBX-115 posts 67% ORR in 15 patients - Stock Titan

Galera Therapeutics (GRTX) agrees to merger with Obsidian; S-4 includes prospectus - Stock Titan

Emerald Bioventures boosts Galera Therapeutics (GRTX) stake to 30.2% after conversion - Stock Titan

Emerald Bioventures boosts common stake in Galera Therapeutics (GRTX) - Stock Titan

GRTX SEC FilingsGalera Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Galera Therapeutics (GRTX) to merge with Obsidian; OBX-115 posts 67% ORR at ASCO - Stock Titan

Galera Therapeutics (NASDAQ: GRTX) agrees to merge with Obsidian; S-4 filed - Stock Titan

Galera Therapeutics Eliminates Series B Preferred, Simplifies Equity - TipRanks

Galera converts remaining Series B preferred into 42.84M common shares - TradingView

Galera Therapeutics (OTCQB: GRTX) ends Series B preferred via full conversion - Stock Titan

Why Is Galera Therapeutics, Inc. (GRTX) Stock Up Today? - Meyka

Galera Therapeutics Expands Share Authorization, Enhances Stockholder Rights - The Globe and Mail

Galera Therapeutics Files 8-K Announcing Amendments to Certificate of Incorporation and Bylaws - Minichart

Galera Therapeutics doubles authorized shares and amends bylaws after stockholder vote - Investing.com UK

Galera Therapeutics doubles authorized shares and amends bylaws after stockholder vote By Investing.com - Investing.com South Africa

Galera Therapeutics (OTCQB: GRTX) doubles share authorization and adds written consent right - Stock Titan

Galera Therapeutics, Inc. 10-Q Quarterly Report: Financial Statements, Management Analysis, and Forward-Looking Statements for 2026 - Minichart

Galera Therapeutics, Inc. 1Q 2026: Net loss $1.61M, EPS $(0.01) — 10-Q Summary - TradingView

Galera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

Galera Therapeutics (NASDAQ: GRTX) bets on Obsidian merger and $350M PIPE - Stock Titan

Galera Shareholders Approve Governance Changes and Share Increase - The Globe and Mail

Galera Therapeutics (OTCQB: GRTX) holders approve share boost and reverse split - Stock Titan

Halper Sadeh LLC is Investigating Whether XOMA, RMAX, GRTX are Obtaining Fair Deals for their Shareholders - GlobeNewswire

Emerald Bioventures details major Galera Therapeutics (GRTX) equity stake - Stock Titan

Malvern-based Galera Therapeutics to be acquired in reverse merger - MSN

Emerald backs Galera–Obsidian deal with 26.5% Galera (GRTX) stake - Stock Titan

Galera, Obsidian Agree to Merge, Raise $350 Million in Financing - MyChesCo

Obsidian CEO Madan Jagasia Leads Merger with Galera Therapeutics Backed by $350M Financing - INDIA New England News

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger-LEG, AVNS, GRTX, and GSAT - The Malaysian Reserve

Halper Sadeh LLC is Investigating Whether LEG, AVNS, SEM, GRTX are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.

Merger Deal: Galera Therapeutics (GRTX) to Merge with Obsidian; ASCO Phase 2 Data Ahead - Stock Titan

Galera Therapeutics (NASDAQ: GRTX) to merge with Obsidian; S-4 and proxy planned - Stock Titan

Galera, Obsidian to Merge, Raise $350 Million in Financing - MyChesCo

Are FORA, GRTX, WBS, TALK Obtaining Fair Deals for their Shareholders? - The Malaysian Reserve

[DEF 14A] Galera Therapeutics, Inc. Definitive Proxy Statement - Stock Titan

United StatesGoodwin Advises Obsidian Therapeutics On Merger With Galera Therapeutics And $350 Million Private Placement Financing - Mondaq

Obsidian, Galera Merger Comes With $350M Infusion for Cancer Drug Trials - MedCity News

Mintz Advising on $350 Million Private Placement Concurrent with Obsidian Therapeutics’ and Galera Therapeutics’ Merger Transaction - Mintz

Galera Therapeutics to merge with Obsidian in $350M deal By Investing.com - Investing.com Australia

Obsidian and Galera reveal reverse merger plan - The Pharma Letter

Obsidian Therapeutics and Galera Therapeutics Enter $350 Million Merger Agreement - Pharmaceutical Executive

Galera (GRTX) to Merge with Obsidian; $350M Financing Backs OBX‑115 - Stock Titan

M&A Class Action Firm Investigating Galera Acquisition - National Today

Galera and Obsidian Announce $350M Merger, Advancing Novel TIL Therapies - National Today

Merger: Galera to combine with Obsidian (NASDAQ: GRTX) with $350M PIPE commitment - Stock Titan

Obsidian Therapeutics (NASDAQ: OBX) to list after merger with Galera, $350M PIPE - Stock Titan

Galera Therapeutics (GRTX) to file Form S-4 for proposed Obsidian merger - Stock Titan

Galera Therapeutics (GRTX) to Merge with Obsidian Therapeutics - GuruFocus

Simile a GRTX